Diagnosis of low-grade inflitrating gliomas—a class of brain tumors that includes diffuse astrocytoma, oligoastrocytoma and oligodendroglioma—currently relies largely on histological classification, although molecular discoveries are beginning to generate new paradigms for diagnosis and management. Bourne and Schiff highlight the molecular abnormalities that have been identified in low-grade gliomas, and discuss how factors such as chromosome 1p19q codeletion andMGMTpromoter methylation status are facilitating stratification of patients in clinical trials.
- T. David Bourne
- David Schiff